TTR and Acute hepatic porphyria: Additionally, siRNA-based therapeutics are extensively researched for various diseases, with five siRNA-based drugs already approved by the FDA for conditions such as hereditary transthyretin amyloidosis (hATTR), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), primary hypercholesterolemia, and amyloid transthyretin-mediated (ATTR) amyloidosis [87].